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BACKGROUND AND PURPOSE
The activation of a9a10 nicotinic cholinergic receptors (nAChRs) present at the synapse between efferent olivocochlear fibres
and cochlear hair cells can prevent acoustic trauma. Hence, pharmacological potentiators of these receptors could be useful
therapeutically. In this work, we characterize ascorbic acid as a positive modulator of recombinant a9a10 nAChRs.
EXPERIMENTAL APPROACH
ACh-evoked responses were analysed under two-electrode voltage-clamp recordings in Xenopus laevis oocytes injected with
a9 and a10 cRNAs.
KEY RESULTS
Ascorbic acid potentiated ACh responses in X. laevis oocytes expressing a9a10 (but not a4b2 or a7) nAChRs, in a
concentration-dependent manner, with an effective concentration range of 1–30 mM. The compound did not affect the
receptor’s current–voltage profile nor its apparent affinity for ACh, but it significantly enhanced the maximal evoked currents
(percentage of ACh maximal response, 240  20%). This effect was specific for the L form of reduced ascorbic acid.
Substitution of the extracellular cysteine residues present in loop C of the ACh binding site did not affect the potentiation.
Ascorbic acid turned into a partial agonist of a9a10 nAChRs bearing a point mutation at the pore domain of the channel
(TM2 V13′T mutant). A positive allosteric mechanism of action rather than an antioxidant effect of ascorbic acid is proposed.
CONCLUSIONS AND IMPLICATIONS
The present work describes one of the few agents that activates or potentiates a9a10 nAChRs and leads to new avenues for
designing drugs with potential therapeutic use in inner ear disorders.
Abbreviations
5HT3, 5-hydroxytryptamine-3 receptors; ASC, ascorbic acid; DHA, D-iso-ASC, D-iso-ascorbic acid; DTNB,
5-5′-dithiobis-2-nitrobenzoic acid; DTT, dehidroascorbate dithiothreitol; nAChRs, nicotinic cholinergic receptors; PAMs,
positive allosteric modulators; TM2, transmembrane region 2
Introduction
The exposure to overly loud sounds is a substantial and
growing health burden in industrialized countries, leading to
hearing loss and tinnitus (Vio and Holme, 2005). The activity
of efferent inhibitory cholinergic fibres projecting from the
brainstem and synapsing onto cochlear hair cells can amel-
iorate acoustic trauma in rodents (Maison et al., 2002;
Taranda et al., 2009). This inhibitory control of auditory func-
tion is mediated by a9a10 nicotinic cholinergic receptors
(nAChRs) coupled to SK2 Ca2+-activated K+ channels, both
present at the postsynaptic membrane of cochlear hair cells
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(Elgoyhen and Katz, 2012). Consequently, enhancing a9a10
receptor-mediated responses by means of a pharmacological
positive modulator could have a potential therapeutic use in
the prevention or treatment of noise induced hearing loss
(Elgoyhen et al., 2009).
The a9a10 nAChR is a very peculiar member of the
nAChR family, since it displays a very distinct pharmacologi-
cal profile that fits neither the muscarinic nor the nicotinic
classification scheme of cholinergic receptors (Verbitsky et al.,
2000; Elgoyhen et al., 2001). Moreover, it shares pharmaco-
logical properties with other members of the Cys-loop family
of receptors, which includes GABAA and GABAC, glycine,
5-hydroxytryptamine-3 (5HT3) and some invertebrate
anionic glutamate receptors (Rothlin et al., 1999; 2003).
Thus, this pharmacologically promiscuous receptor is sensi-
tive to a wide variety of antagonists including glycinergic,
gabaergic, serotonergic (Rothlin et al., 1999; 2003) as well as
nicotinic and muscarinic antagonists (Verbitsky et al., 2000),
ototoxic drugs like aminoglycoside antibiotics (Rothlin et al.,
2000) and quinine derivatives (Ballestero et al., 2005), the
NMDA antagonist neramexane (Plazas et al., 2007), some
conotoxins (Johnson et al., 1995; McIntosh et al., 2005;
Ellison et al., 2006) and opioid peptides and morphine
(Lioudyno et al., 2002). Furthermore, nicotine and other
nicotinic agonists like cytisine and epibatidine behave as
antagonists of the a9a10 nAChRs (Verbitsky et al., 2000;
Elgoyhen et al., 2001). Despite this relatively large number of
antagonists characterized for a9a10 receptors, only one phar-
macological potentiator is known to date, ryanodine (Zorrilla
de San Martin et al., 2007), which is not suitable for use in
therapeutics. Therefore, finding novel positive modulators of
the a9a10 nAChR that can be used clinically would represent
a significant breakthrough, with potential use in noise-
induced acoustic trauma.
Many drugs that have been tested as otoprotectants are
antioxidant or related to antioxidant metabolism (Lynch and
Kil, 2005). In this regard, it has been demonstrated that
vitamin C, that is ascorbic acid (ASC), can prevent acoustic
trauma in guinea pigs (McFadden et al., 2005), but the under-
lying mechanism remains unclear. Several lines of evidence
suggest that reducing agents scavenge free radicals produced
during noise exposure (Le Prell et al., 2007; Heinrich et al.,
2008), but other underlying mechanisms could account for
this protectant effect. ASC is an endogenous antioxidant
which is present in ~0.05 mM concentrations in plasma
(Evans et al., 1982), ~0.2 mM in CSF (Reiber et al., 1993; Miele
and Fillenz, 1996) and ~1 mM in whole brain (Spector and
Johanson, 2006; Harrison and May, 2009). In certain tissues
like the retina, concentrations of ASC are 100 times more
concentrated than in plasma (Rose and Bode, 1991; Hediger,
2002). Particularly, in blood cells it reaches ~3 mM concen-
trations (Evans et al., 1982) and in neurons 10 mM concen-
trations (Rice and Russo-Menna, 1998). Extracellular ASC
levels can transiently rise substantially during neuronal activ-
ity (Bigelow et al., 1984; Grunewald, 1993; Rebec and Pierce,
1994; Portugal et al., 2009). It has been shown that ASC
modulates the activity of several ion channels like NMDA
glutamate receptors and T-type Ca2+ channels (Majewska
et al., 1990; Nelson et al., 2007). Interestingly, in contrast to
the effect of ASC on the above-mentioned channels where it
decreases responses, it has been demonstrated recently that
ASC potentiates responses through GABAA and GABAC recep-
tors (Calero et al., 2011). In the present work, we analysed the
effect of ASC on other members of the Cys-loop family of
receptors, namely the recombinant a7, a4b2 and a9a10
nAChRs. We show that ACh-evoked responses of a9a10
nAChRs expressed in Xenopus oocytes, but not a7 and a4b2,
were potentiated by ASC in a concentration-dependent,
stereo-specific, reversible and voltage-independent manner.
The potentiating effect could involve an allosteric mecha-
nism. The present results indicate that enhanced efferent
activity to cochlear hair cells might account in part for the
otoprotectant effect of ASC. In addition, they open the pos-
sibility of designing related compounds with improved prop-
erties for therapeutic use.
Methods
Expression of recombinant receptors in
Xenopus laevis oocytes
For expression studies, a4, a7, a9, a10 and b2 rat nAChR
subunits were subcloned into a modified pGEMHE vector.
Capped cRNAs were in vitro transcribed from linearized
plasmid DNA templates using RiboMAXTM Large Scale RNA
Production System (Promega, Madison, WI). Mutant subunits
were produced using Quick change XL II kit (Stratagene, La
Jolla, CA). The maintenance of X. laevis and the preparation
and cRNA injection of stage V and VI oocytes have been
described in detail elsewhere (Verbitsky et al., 2000). Typically,
oocytes were injected with 50 nL of RNase-free water contain-
ing 0.01 to 1.0 ng of cRNA (at a 1:1 molar ratio when pairwise
combined) and maintained in Barth’s solution at 18°C. Elec-
trophysiological recordings were performed 2 to 6 days after
cRNA injection under two-electrode voltage clamp with an
Oocyte Clamp OC-725B or C amplifier (Warner Instruments
Corp., Hamden, CT). Recordings were filtered at a corner
frequency of 10 Hz using a 900BT Tunable Active Filter (Fre-
quency Devices Inc., Ottawa, IL). Data acquisition was per-
formed using a Patch Panel PP-50 LAB/1 interphase (Warner
Instruments Corp., Hamden, CT) at a rate of 10 points per
second. Both voltage and current electrodes were filled with
3 M KCl and had resistances of ~1 MW. Data were analysed
using Clampfit from the pClamp 6.1 software. During electro-
physiological recordings, oocytes were continuously super-
fused (~15 mL·min-1) with normal frog saline composed of
115 mMNaCl, 2.5 mM KCl, 1.8 mMCaCl2 and 10 mMHEPES
buffer, pH 7.2. Acetylcholine, ASC, D-iso-ascorbic (D-iso-ASC)
acid, dehidroascorbate (DHA), dithiothreitol (DTT) and 5-5′-
dithiobis-2-nitrobenzoic acid (DTNB) were added to the per-
fusion solution for application. Unless otherwise indicated,
themembrane potential was clamped to -70 mV. Tominimize
activation of the endogenous Ca2+-sensitive chloride current
(Elgoyhen et al., 2001), all experiments were performed in
oocytes incubated with the Ca2+ chelator BAPTA-AM
(100 mM) for 3 h before electrophysiological recordings.
Concentration–response curves were normalized to the
maximal agonist response in each oocyte. The mean and
SEM of peak current responses are represented. Agonist
concentration–response curves were iteratively fitted, using
Prism 5 software (GraphPad Software Inc., La Jolla, CA), with
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the following equation: I/Imax = AnH/(AnH + EC50nH), where I is
the peak inward current evoked by agonist at concentration A;
Imax is the current evoked by the concentration of agonist
eliciting a maximal response; EC50 is the concentration of
agonist inducing half-maximal current response and nH is the
Hill coefficient. Current–voltage (I–V) relationships were
obtained by applying 2-s voltage ramps from -120 to -50 mV,
10 s after the peak response to 10 mM ACh from a holding
potential (Vhold) of -70 mV. Leakage correction was performed
by subtraction of the current–voltage curve obtained by the
same voltage ramp protocol before the application of ACh.
Data were analysed using Clampfit from the pClamp 6.1
software. Some of our data sets did not fit to a standard
Gaussian distribution, tested using Kolmogorov–Smirnov,
D’Agostino–Pearson or Shapiro–Wilk tests. Thus, statistical
significance was evaluated using Mann–Whitney; P < 0.05
was considered significant. Correlation was evaluated using
Pearson correlation test; P < 0.05 was considered significant.
Materials
All drugs were obtained from Sigma-Aldrich (St. Louis, MO).
ACh chloride was dissolved in distilled water as 100 mM
stocks and stored aliquoted at -20°C. BAPTA-AM was stored
at -20°C as aliquots of a 100 mM solution in dimethyl sul-
foxide (DMSO), thawed and diluted 1000-fold into Barth’s
solution shortly before incubation of the oocytes. ASC, D-iso-
ASC, DHA and DTT solutions in Ringer’s saline were freshly
prepared immediately before application. The pH was
adjusted with NaOH when required. When NaOH was added
to solutions to adjust the pH, Na+ concentration was adjusted
to remain at 115 mM to avoid changes in the ion’s driving
force. ASC, D-iso-ASC and DHA solutions were always covered
to avoid exposure to light. DTT solutions were prepared in
the presence of 10 mM tricine in order to avoid any interfer-
ence of zinc traces (Pan et al., 2000). DTNB was dissolved in
DMSO to reach a 250 mM concentration and then diluted
1000-fold in frog saline immediately before application. All
studies involving animals are reported in accordance with the
ARRIVE guidelines for reporting experiments involving
animals (McGrath et al., 2010). All experimental protocols
were carried out in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals
(NIH Publications no. 80-23) revised 1978. The drugs and
receptors names mentioned in the manuscript conform to
BJP’s Guide to Receptors and Channels (Alexander et al., 2011).
Molecular homology modelling
Homology models for the extracellular domain of the rat
a9a10 receptor were constructed using Modeller 9v8 software
(Sali and Blundell, 1993), considering the known stoichiom-
etry (Plazas et al., 2005b) and an alternate subunit assembly,
using the Aplysia californica AChBP apo form crystallography
(2W8E.pdb) as a template.
Results
Effect of ASC on responses to ACh of
recombinant a9a10 nAChRs
Figure 1A shows representative responses evoked by the
reported EC50 concentration of ACh, 10 mM (Elgoyhen et al.,
2001), in X. laevis oocytes expressing rat a9a10 nAChRs. The
co-application of 3 mM ASC potentiated responses to the
agonist. Potentiation was reversible since initial control
responses to ACh were recovered after washing the oocytes
with frog saline for 3 min. Pre-incubation with ASC for 5 min
did not further modify its potentiating effect (data not
shown). In addition, ASC per se did not have an effect on
a9a10 expressing oocytes. Figure 1B shows a scatter plot to
depict that the potentiating effect of ASC was quite variable.
This variability was not correlated with the expression level of
the receptor in oocytes (P = 0.1139, Pearson test). The mean
magnitude of potentiation by 3 mM ASC, expressed as the
percentage of the response to 10 mM ACh, was 165  6% (n =
77, eight frogs). As shown in Figure 1C, 3 mM ASC did not
change the macroscopic current decay kinetics of responses
to 100 mM acetylcholine, assessed evaluating the relation
between the current amplitude at 20 s after reaching the
maximum (I20) and current amplitude at the peak (I20/Imax
control: 66  8%; plus ASC: 60  10, n = 4, two frogs; P = 0.99
Mann–Whitney test). A possible intracellular effect was ruled
out as the injection of oocytes with ASC (to reach a final
3 mM concentration) did not produce a significant effect on
ACh evoked currents (Figure S1).
In order to test if ASC also potentiates other nAChRs, the
effect was analysed on a4b2 and a7 nAChRs (Figure 2).
Responses to an EC50 concentration of ACh was not modified
Figure 1
Effect of ASC on responses to ACh of recombinant a9a10 nAChRs.
(A) Responses evoked by ACh either alone, plus 3 mM ASC or after a
3 min wash, in oocytes expressing a9a10 nAChRs (representative of
n = 77, eight frogs). (B) Scatter plot displaying the experimental
variability of the responses to the application of 10 mM ACh alone
(n = 10, two frogs) or co-applied with 3 mM ASC (n = 77, eight
frogs). Peak current values are shown, expressed as the percentage of
the peak control current elicited by 10 mM ACh alone. The mean and
SEM for each group is shown in black; *P < 0.0001 Mann–Whitney
test. (C) Representative responses (of n = 4 repetitions, two frogs),
scaled to the same peak amplitude, evoked by a 1 min application of
100 mM ACh either alone or co-applied with 3 mM ASC, in oocytes
expressing a9a10 nAChRs.
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by the co-application of 3 mM ASC in the case of a4b2 (per-
centage of 10 mM ACh response, 102  4%, n = 15, three
frogs) and a7 nAChRs (percentage of 100 mM ACh response,
105  4%, n = 16, three frogs). A 10 mM concentration of
ASC inhibited responses to ACh of a4b2 and a7 nAChRs
(Figure S2).
As shown in Figure 3, the potentiating effect of ASC
on ACh-evoked currents through a9a10 receptors was
concentration-dependent. Figure 3B shows a concentration–
response curve for the potentiating effect of ASC performed at
10 mM ACh (n = 4–13 per point, four frogs). Potentiation was
significant at 1 mM or higher concentrations of ASC and did
not saturate at the maximal concentration tested (30 mM). To
rule out a possible osmotic effect of applying ASC solutions
of such concentrations we applied 3, 10 and 30 mM ASC,
without ACh, and observed no change in the leak currents
(data not shown). In addition, the application of sucrose
solutions isoosmotical to 3, 10 or 30 mM ASC solutions,
produced no effect on the leak currents and did not potenti-
ate ACh responses (data not shown). To further characterize
this potentiating effect, concentration–response curves to
ACh were performed in the presence or absence of 3 mM
ASC. As shown in Figure 4A, ASC produced a significant
increase in the agonist maximal response (percentage of
maximal response, 240  20%, n = 6, three frogs) and no
change in the EC50 (control, 16  1 mM; 3 mM, ASC 18 
1 mM; n = 5–12, three frogs) or Hill coefficient (control, 1.05
0.05; 3 mM ASC, 0.8 0.1; n = 5–12, three frogs). In addition,
the effect was not voltage-dependent (Figure 4B). Thus,
potentiation was equally observed at depolarized (percentage
of ACh response at +40 mV: 130  14%, n = 10, two frogs)
and hyperpolarized (percentage of ACh response at -90 mV:
137  10%, n = 10, two frogs) potentials, and there was no
change in the reversal potential (control: -5  2 mV; 3 mM
ASC, -7  3 mV, n = 10, two frogs).
We tested two structurally related analogs: DHA, the oxi-
dized product of ASC, which lacks antioxidant activity, and
the stereoisomer D-iso-ASC, which has the same antioxidant
activity as ASC (Figure 5A). In a9a10 expressing oocytes,
neither 3 mM DHA nor 3 mM D-iso-ASC potentiated
responses evoked by 10 mM ACh. In fact, at ACh concentra-
tions lower than 10 mM, they both inhibited a9a10 receptor
currents (Figure 5B). Inhibition was only observed at concen-
trations of ACh lower than 10 mM. To test if the presence of
D-iso-ASC could influence the effect of ASC, as they are very
similar molecules, we co-applied both compounds at a 3 mM
concentration with ACh, using an agonist concentration at
which D-iso-ASC produced no effect per se (10 mM, Figure 5B).
Potentiation was not significantly different in the presence or
absence of 3 mM D-iso-ASC (percentage of ACh response:
3 mM ASC, 131  8%; +3 mM D-iso-ASC, 130  11%; n = 6,
three frogs; P = 0.8182, Mann–Whitney; data not shown).
Taken together, these results indicate that the potentiation
effect is exclusive of the reduced L form of ASC.
Contribution of redox sensitive extracellular
residues to the potentiation by ASC
Potentiation by ASC could derive from at least two different
mechanisms: redox modulation or the binding to an allos-
teric potentiating site. In an attempt to gain insight into the
mechanism underlying the potentiating effect of ASC, we
first tested whether the a9a10 nAChR is sensitive to modu-
lation by redox agents. Co-application of 10 mM ACh
together with the reducing agent DTT (2 mM) potentiated
a9a10 receptor currents (percentage of control response, 230
 30%, n = 24, four frogs). On the other hand, co-application
Figure 2
Effect of ASC on responses to ACh of recombinant a4b2 or a7
nAChRs. Responses evoked by ACh either alone, plus 3 mM ASC or
after a 3 min wash, in oocytes expressing a4b2 or a7 nAChRs (rep-
resentative of n = 15, three frogs; n = 16, three frogs respectively).
Figure 3
Concentration-dependent effect of ASC on the recombinant a9a10
nAChR. (A) Representative traces of responses evoked by 10 mM ACh
either alone or co-applied with increasing concentrations of ASC
in oocytes injected with a9 and a10 cRNAs. (B) Concentration–
response curve constructed by performing co-applications of 10 mM
ACh and increasing concentrations of ASC. Peak current values are
shown, expressed as the percentage of the peak control current
elicited by 10 mM ACh alone. The mean and SEM of 4 to 13 experi-
ments per group, using oocytes from four frogs, are shown. *P < 0.05
Mann–Whitney test.
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of 10 mM ACh and the oxidizing agent DTNB (250 mM) inhib-
ited a9a10 receptor currents (percentage of inhibition, 33 
4%, n = 17, three frogs). Figure 6A shows representative
responses, and Figure 6B shows quantification of results. As
previously observed with ASC, potentiation by DTT was very
variable. On the other hand, the degree of inhibition by
DTNB was quite reproducible (Figure 6C). The effects of DTT
and DTNB were readily reversible after 3 min wash of the
oocytes with frog saline solution. Neither, 2 mM DTT nor
250 mM DTNB elicited responses in a9a10 injected oocytes
(data not shown). These results indicate that the a9a10 is
sensitive to redox modulation.
Cysteine residues are subject to rapid and reversible redox
modification in physiological conditions, which makes them
the most likely candidate target for a redox mechanism of
modulation (Klomsiri et al., 2011). In addition, there is evi-
dence showing that ASC is able to reduce disulfide bridges in
vitro (Landino et al., 2006). The a9 and a10 subunits have
four highly conserved extracellular cysteines, two consecu-
tive ones (C192 and C193, Torpedo marmorata a numbering)
in loop C, characteristic of the principal component of the
binding site of a subunits and two additional ones that form
the Cys-loop disulfide bond characteristic of the family (C128
and C142, T. marmorata a numbering). We analysed the effect
of ASC in oocytes expressing mutant a9 and a10 subunits
with the two consecutive Cys residues in loop C substituted
by serine. Mutant a9a10 CC192/193SS receptors responded
to ACh with an EC50 of 983  84 mM and a Hill coefficient of
1.1  0.2 (n = 7, three frogs) (Figure 7A, B). Responses to ACh
were potentiated by 3 mM ASC. As shown in Figure 7B, and
as previously seen for wild-type receptors (Figure 4A), ASC
produced a significant increase in the agonist maximal
response (percentage of maximal response, 160  10%, n = 6,
three frogs) and no change in the EC50 (798  44, n = 6, three
frogs) or Hill coefficient (1.2  0.2, n = 6, three frogs). In
addition, the effect was not voltage-dependent (Figure 7C).
Thus, potentiation was equally observed at depolarized (per-
centage of ACh response at +40 mV: 160  20%, n = 6, two
frogs) and hyperpolarized (percentage of ACh response at
-90 mV: 155  16%, n = 6, two frogs) potentials, and there
was no change in the reversal potential (control: -8  2 mV;
3 mM ASC, -13  3 mV, n = 6, two frogs). These results
indicate that a direct effect of ASC on the contiguous CC192/
193 does not contribute to its potentiating effect. Consist-
ently, the presence of the cysteine to serine substitutions in
only a9 or a10 single mutant receptors did not abolish the
potentiation by ASC (Figure S3).
It has been shown that mutations of the cysteine residues
that form the Cys-loop disulfide bond lead to non-functional
or non-expressing nAChRs in X. laevis oocytes (Dunckley
et al., 2003). Therefore, mutating these residues was not an
option and the participation of the cysteine residues of the
Cys-loop to the potentiating effect of ASC was not tested.
The transmembrane 2 mutation V13T
converts ASC from a potentiator to an agonist
Gill et al. (2011) have shown that TQS, an allosteric poten-
tiator of a7 nAChRs, becomes an agonist of mutant L9′T a7
receptors. Figure 8A shows representative responses evoked
by 3 mM ASC and control responses to a saturating (3 mM)
ACh in X. laevis oocytes expressing rat a9 and a10 subunits
bearing the V13′T mutation, which produces similar but
more pronounced effects than those of the L9′T mutation
(Plazas et al., 2005a). ASC elicited inward currents in a
concentration-dependent manner, with a maximal effect that
was 20  4% (n = 5, two frogs) of that observed with a
saturating 3 mM ACh concentration (Figure 8A, B). On the
contrary, in the presence of 3 mM D-iso-ASC, outward cur-
rents were observed which were 14  3% (n = 6, two frogs) of
currents elicited by 3 mM ACh (Figure 8C). In addition, 2 mM
Figure 4
Characterization of the potentiating effect of ASC on recombinant a9a10 nAChRs. (A) Concentration–response curves to ACh performed either
alone or in the presence of 3 mMASC (filled circles). Peak current values were normalized and referred to themaximal peak response to ACh (1 mM).
The mean and SEM of 5 to 12 experiments per group, using oocytes from three frogs, are shown. *, significantly different form control, P < 0.05
Mann–Whitney test. (B) Representative (n = 10, 2 frogs) I–V curve obtained in the presence of 10 mMACh either alone (grey) or co-appliedwith 3 mM
ASC (black). A 2 s voltage ramp from -120 to 50 mVwas applied at the plateau phase of the response obtained ina9a10 expressing oocytes clamped
at -70 mV. Currents were leak-corrected by subtracting the response to the same voltage ramp obtained prior to the application of ACh.
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DTT also elicited outward currents (percentage of ACh 3 mM
response; 23  4, n = 6, two frogs). Taken together, these
results suggest that an allosteric potentiation mechanism
rather than a redox effect might contribute to the action of
ASC on a9a10 nAChRs.
Contribution of extracellular arginine residues
to the potentiation by ASC
The ASC interaction site has been characterized in a number
of proteins (Pande and Myer, 1980; Burmeister et al., 2000;
Sharp et al., 2003; Mishra et al., 2009). In all of these, arginine
directly interacts with ASC. Consequently, we searched for
extracellular arginine residues in a9 and a10 subunits. To
narrow down the number of candidate arginine residues, we
focused on those present at, or close to, domains related to
receptor gating (Bartos et al., 2009). To this end, we con-
structed molecular homology models for the extracellular
domain of the a9a10 receptor, considering the known stoi-
chiometry (Plazas et al., 2005b) and an alternate subunit
assembly, using the Aplysia californica AChBP apo form
(2W8E.pdb) as a template. Of the many extracellular arginine
residues present in a9 and a10 subunits, we focused on two
(Figure 9A), one close to the ACh binding site in loop D (R57)
and another one at the b1-b2 loop (R46). Other arginine
residues were either not exposed at the surface of the mol-
ecule, which would make them inaccessible to ASC in solu-
tion, or were not located in sites of the molecule known to be
related to channel gating. To analyse the influence of these
residues on the effect of ASC, we substituted them to alanine
to produce mutant a9 and a10 subunits. Figure 9B shows that
currents elicited by two different concentrations of ACh in
R46A mutant a9a10 nAChRs were potentiated by co-applied
3 mM ASC (percentage of 10 mM ACh response, 179  9%,
n = 7, three frogs). Similar results were obtained with R57A
mutant receptors (Figure 9C, percentage of 100 mM ACh
response, 152  5%, n = 4, two frogs). Thus, arginine residues
R46 and R57 are most likely not involved in the effect of ASC.
Discussion and conclusions
The present work shows that ASC at high micromolar-low
millimolar concentrations potentiates ACh-elicited responses
in Xenopus oocytes expressing the a9a10 nAChR. To the best
of our knowledge, this is the first report of a potentiating
effect of ASC on a nAChR and adds to the previously
described action of this compound on GABAA and GABAC
receptors (Calero et al., 2011), members also of the Cys-loop
family of ligand-gated ion channels (Thompson et al., 2010).
The effect is not a broad one over nAChRs in general, since
a4b2 and a7 receptors were not subject to potentiation. The
effective potentiating concentration of ASC on the a9a10
nAChRs is similar to that described for GABAA and GABAC
receptors and within the concentration that can be attained
in neuronal tissues. Thus, this endogenous redox agent is
highly concentrated in several regions of the CNS and is
accumulated in neurons and glial cells by specific transport-
ers (Harrison and May, 2009; Corti et al., 2010). It is present at
high micromolar concentrations in the cerebrospinal fluid
and millimolar concentrations within cells (Evans et al.,
1982; Reiber et al., 1993; Miele and Fillenz, 1996; Rice and
Russo-Menna, 1998; Spector and Johanson, 2006), and in
neurons, the concentration may reach as high as 10 mM (Rice
and Russo-Menna, 1998; Rice, 2000). In certain tissues like
the retina, concentrations of ASC are 100 times more con-
centrated than in plasma (Rose and Bode, 1991; Hediger,
2002). Moreover, the extracellular concentration of ASC can
transiently undergo substantial increases during neuronal
activity under physiological or pathological conditions
(Bigelow et al., 1984; Grunewald, 1993; Rebec and Pierce,
1994; Portugal et al., 2009). Neither the concentration of ASC
in cochlear fluids nor within hair cells, nor the expression of
ASC transporters in the cochlea has been investigated.
However, it is likely that, as reported for other tissues, micro
Figure 5
Effect of different ASC analogs on responses to ACh of recombinant
a9a10 nAChRs. (A) Chemical structure of L- ASC, DHA and D-iso-
ASC. (B) Quantification of the effect of 3 mM DHA or D-iso-ASC on
currents evoked by increasing concentrations of ACh. Peak current
values obtained by the co-application of ACh and each of the com-
pounds were normalized and referred to the control peak response
to ACh for each ACh concentration. The mean and SEM of 3 to 8
experiments per group, using oocytes from two frogs, are shown.
*P < 0.05 Mann–Whitney test.
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to millimolar concentrations of ASC are present in or around
hair cells or might be attained under pathophysiological con-
ditions such as trauma.
The fast onset, fast offset and reversible character of the
effect of ASC on a9a10 nAChRs receptors suggest that it is
not due to its entry into the cells. This is in agreement with
the fact that pre-incubation with ASC did not enhance the
potentiating effect (data not shown). Moreover, oocytes do
not express ASC transporters (SCVT1 and SCVT2) (Dyer et al.,
1994); and, being a hydrophilic compound, ASC does not
cross the lipid bilayer. In addition, the injection of ASC into
oocytes did not modify ACh-evoked currents. Based on this
evidence an extracellular superficial site of action is likely.
One possible explanation for the observed action of ASC is
via an antioxidant effect. It has been reported that nAChRs
are subject to redox modulation. Thus, DTT reduces the
maximal binding of nicotine or the binding affinity of
a-bungarotoxin in total rat brain preparations (Stitzel et al.,
1988) and the responses of nAChRs present in PC12 cultured
cells (Leprince, 1983). In addition, reduction by DTT followed
by alkylation in the presence of NEM results in nAChRs
with decreased open times and single-channel currents in
BC3H-11 cells (Bouzat et al., 1991). The observation that DTT
potentiated and DTNB inhibited currents through the a9a10
nAChR indicates that this receptor is also subject to redox
modulation, albeit in the opposite direction to that reported
for other nAChRs and similar to that described for GABAA and
GABAC receptors (Amato et al., 1999; Pan et al., 2000; Calero
and Calvo, 2008). Previous studies have suggested that
cysteine residues are commonly involved in the redox modu-
lation of various ion channels (Ruiz-Gomez et al., 1991; Rup-
persberg et al., 1991; Sullivan et al., 1994; Chu et al., 2006).
The fact that the potentiating effect of ASC was still observed
in the a9a10 CC192/193SS mutant receptor precludes the
participation of these residues in a possible redox effect of
ASC. The observation that DHA, the oxidized product of ASC,
did not potentiate but decreased the amplitude of responses
to low concentrations of ACh could speak towards an anti-
oxidant effect of ASC over the a9a10 nAChR. However, one
cannot exclude the possibility that both ASC and DHA are
binding to different sites within the receptor and producing
opposite effects (e.g. a competitive antagonism in the case of
DHA and a positive allosteric modulation in the case of ASC).
Moreover, the –OH groups only present in ASC might be
required for recognition of a putative binding site within the
receptor. The observation that the potentiating effect of ASC
was stereoselective since D-iso-ASC, ASC’s stereoisomer with
equal antioxidant activity, did not potentiate responses to
ACh might speak towards the existence of a binding site for
the compound resulting in a positive allosteric mechanism of
action, as reported for several novel compounds acting upon
other nAChRs (Iorga et al., 2006; Bertrand et al., 2008; Young
et al., 2008; Arias et al., 2011; Gill et al., 2011). Although the
potentiating effect of ASC was not inhibited by 3 mM D-iso-
ASC, it is possible that they both bind to the same site but
with different affinities, and that very high millimolar D-iso-
ASC concentrations are needed in order to overcome the
effect of ASC.
Positive allosteric modulators (PAMs) have a long and
successful clinical track record exemplified by the benzodi-
azepine family of drugs (e.g. diazepam), which function as
allosteric modulators of GABAA receptors (Bateson, 2004). In
recent years, positive allosteric modulators (PAMs) mostly of
a7 and a4b2 nAChRs have emerged. These compounds rein-
force the endogenous cholinergic neurotransmission without
directly stimulating the target receptors (Bertrand and
Gopalakrishnan, 2007; Arias, 2010). PAMs do not bind to the
ACh orthosteric binding sites but allosterically enhance the
Figure 6
Effect of reducing and oxidizing agents on ACh-evoked currents. (A) Representative traces of responses evoked by the co-application of 10 mM
ACh and 2 mM DTT (upper panel, n = 24, four frogs) or 250 mM DTNB (lower panel, n = 17, three frogs). DTT was co-applied with 10 mM tricine
to rule out an effect of Zn2+ traces. (B) Quantification of the effect of DTT and DTNB on currents evoked by 10 mM ACh. Effect of ASC was included
for the sake of comparison. Peak current values were normalized and referred to the peak response to 10 mM ACh. The mean and SEM of 6 to
24 experiments per group, using oocytes from at least two frogs, are shown. *P < 0.05 Mann–Whitney test. (C) Scatter plot displaying the
experimental variability of the responses to the application of 10 mM ACh alone (n = 10, two frogs), co-applied with 2 mM DTT (n = 24, four frogs)
or 250 mM DTNB (n = 17, three frogs). Peak current values are shown, expressed as the percentage of the peak control current elicited by 10 mM
ACh alone. The mean and SEM for each group is shown in black. *P < 0.05 Mann–Whitney test.
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activity elicited by agonists by increasing the gating process
and mainly affecting the peak current response (type I)
and/or by decreasing desensitization (type II). The observa-
tion that ASC increased responses to ACh without modifying
the macroscopic current decay kinetics would possibly clas-
sify it as a type I PAMs. However, type I PAMs in general also
increase the apparent affinity of the agonist (Arias, 2010), an
effect that was not observed in the case of ASC potentiation
of the a9a10 nAChR. Thus, the classification of PAMs could
be oversimplified, and future analyses might incorporate new
mechanisms mediating allosteric modulation. It has been
reported that the a7 PAM TQS behaves as an agonist of the
L9′T mutant receptor (Gill et al., 2011), a receptor that has
increased gating properties and spontaneous openings in the
absence of the agonist (Labarca et al., 1995). In accordance to
described models for allosteric proteins (Monod et al., 1965),
the agonist effect of TQS has been explained in terms of its
influence on rate constants for transitions between resting
and open states of the receptor, favoring the open state (Gill
et al., 2011). A similar effect of ASC can be hypothesized,
since it also becomes a partial agonist of the V13′T a9a10
nAChR. In addition, the fact that D-iso-ASC does not behave
as an agonist of the V13′T mutant receptor but produces a
deflection of the baseline current in the positive direction
(that most likely results from the closure of spontaneously
opened mutant receptors) (Plazas et al., 2005a) could suggest
that it binds to the ASC binding site and acts as a negative
allosteric modulator, a mechanism of action reported for
some compounds acting on nAChRs (Arias, 2010). Moreover,
the observation that the reducing agent DTT produces a posi-
tive deflection of the leak current and not an inward current
as observed with ASC indicates that an antioxidant effect is
probably not the underlying mechanism of action of ASC on
the a9a10 nAChR. Although arginine residues have been
described to be at the interaction site with ASC in proteins
that have been crystalized with this compound (Pande and
Myer, 1980; Burmeister et al., 2000; Sharp et al., 2003; Mishra
et al., 2009), they seem not to play a role in the case of the
a9a10 receptor. Several amino acid residues present at both
the extracellular or transmembrane portions of the nAChR
have been reported to be involved in the site of action of
PAMs (Arias, 2010). Further experiments that will involve
molecular docking and the generation of chimeric and
mutant receptors will aid to delineate the site of action of ASC
on the a9a10 nAChR.
Does the potentiating effect of ASC on a9a10 nAChRs
have a potential physiological or pathophysiological role?
Antioxidants prevent cochlear damage from toxic reactive
Figure 7
Role of extracellular Cys residues in the potentiation by ASC.
(A) Responses evoked by ACh either alone, plus 3 mM ASC or after a
3 min wash, in oocytes expressing mutant a9 and a10 subunits with
CC 192/193 SS substitutions (Torpedo a1 numbering) (n = 6, three
frogs). (B) Concentration–response curves to ACh either alone or in
the presence of 3 mM ASC (black circles) obtained in oocytes
expressing mutant a9 and a10 subunits with CC 192/193 SS sub-
stitutions. Peak current values were normalized and referred to the
maximal peak response to ACh. The mean and SEM of 6 to 7
experiments, using oocytes from three frogs, per group, are shown.
*P < 0.05, Mann–Whitney test. (C) Representative (n = 6, two frogs)
I–V curve obtained in the presence of 1 mM ACh either alone (grey)
or co-applied with 3 mM ASC (black). A 2 s voltage ramp from -120
to 50 mV was applied at the plateau phase of the ACh response
obtained in oocytes expressing CC 192/193 SS mutant a9a10
nAChRs clamped at -70 mV. Currents were leak-corrected by sub-
tracting the response to the same voltage ramp obtained prior to the
application of acetylcholine.
Figure 8
ASC is a partial agonist of a9a10 V13′T mutant receptors. (A) Rep-
resentative traces of responses evoked by 10 mM ASC and by a
saturating concentration of ACh (3 mM), in oocytes expressing V13′T
mutant a9a10 receptors (n = 5, two frogs). (B) Concentration–
response curve to ASC in oocytes expressing V13′T mutant a9a10
receptors. Peak current values were normalized and referred to the
peak response to a saturating 3 mM ACh concentration. The mean
and SEM of five experiments per concentration, using oocytes from
two frogs, are shown. (C) Representative traces of the effect of 3 mM
D-iso-ASC and 2 mM DTT in V13′T mutant a9a10 receptors (n = 6 in
all cases, using oocytes from at least two frogs).
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oxygen species that are produced at high levels during and
after noise exposure (Lynch and Kil, 2005; Le Prell et al.,
2007). In particular, it has been described in rodents that ASC
is beneficial in reducing the sensitivity to noise-induced
hearing loss (McFadden et al., 2005). Thus, in addition to its
antioxidant effects and based on the described protective
effect of the medial olivocochlear system (Maison et al., 2002;
Taranda et al., 2009), potentiation of responses mediated by
a9a10 nAChRs at the efferent-hair cell synapse might also
play a role.
In summary, we report that a9a10 nAChR responses are
potentiated by ASC. This is an important contribution to the
pharmacology of this receptor, for which few positive modu-
lators have been described and paves the way to the design of
clinically useful compounds for inner ear pathologies.
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online version of this article:
Figure S1 Effect of ASC injection on a9a10 responses to
ACh. (A) Responses evoked by 10 mM ACh prior to injection
of 4.6 nL (mean oocyte volume ~300 nL) of 300 mM ASC, pH
balanced with equimolar KOH, 5 s and 5 min after injection
(representative of n = 4, one frog). Arrowheads show time
of injection. (B) Responses evoked by 10 mM ACh prior to
control injection of 4.6 nL of 300 mM KCl, 5 s and 5 min
after injection (representative of n = 4, one frog). (C) Scatter
plot displaying the experimental variability of the injection
of ASC on the responses to 10 mM ACh (n = 4, 1 frog) or the
effect of the control injection with KCl (n = 4, one frog). Peak
current values are shown only for the 5 s responses, expressed
as the percentage of the peak control current elicited by
10 mM ACh prior to injection. The mean and SEM for each
group is shown in black; P = 0.07, Mann–Whitney test.
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Figure S2 Effect of 10 mM ASC on responses to ACh of
recombinant a4b2 or a7 nAChRs. Responses evoked by ACh
either alone, plus 10 mM ASC or after a 3 min wash, in
oocytes expressing a4b2 or a7 nAChRs (representative of
n = 6, two frogs).
Figure S3 Role of extracellular Cys residues in the potentia-
tion by ASC. Responses evoked by ACh either alone, plus
3 mM ASC or after a 3 min wash, in oocytes expressing
mutant a9 or a10 subunits with CC 192/193 SS substitutions
(Torpedo a1 numbering) (n = 3, one frog).
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